Product
Naxitamab + GM-CSF
1 clinical trial
2 indications
Indication
NeuroblastomaIndication
Soft Tissue CancerClinical trial
A Phase II Single Center Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor (GM CSF and Ifosfamide Carboplatin Etoposide) For Patients With Relapsed Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory NeuroblastomaStatus: Completed, Estimated PCD: 2023-07-20